ClinicalTrials.gg
RecruitingNCT05836987REACT-AFUpdated Nov 3, 2026

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

A Phase 3 interventional study of AFSW Guided DOAC and Continuous DOAC therapy in Atrial Fibrillation, sponsored by Johns Hopkins University. Recruiting at 93 sites in United States. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Johns Hopkins University · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.
Updated Nov 3, 2026Site recruiting status changedEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,350
Allocation
Randomized
Ages
22 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Atrial Fibrillation by Johns Hopkins University — 3 open to participants now, 3 under way, 1 of them phase 3. Atrial Fibrillation · Johns Hopkins University.

Planned enrollment
Largest of 10
5,350 · median 64
Started
2023
with 1 other
Phase 3
Only one
of the 10
Registered
8th of 10
by date

Among the 10 studies in Atrial Fibrillation by Johns Hopkins University, this one has the largest planned enrollment, is one of 2 that started in 2023, is the only one in phase 3, and was the 8th registered.

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 964 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 10 studies in Atrial Fibrillation by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 610 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 22 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Atrial Fibrillation by Johns Hopkins University, or all of them as a file.
02

Study summary

REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.

Read the detailed description

REACT-AF is a prospective, unblinded, randomized (1:1 allocation), multi-center, investigational clinical trial of men and women aged 22-85 with a documented history of symptomatic or asymptomatic paroxysmal or persistent (AF) and a moderate risk of stroke measured by CHA2DS2-VASc score 1-5 for men, 2-5 for women (which stands for Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), Vascular disease, age 65 to 74 and sex category (female)). Participants randomized to the experimental arm (on demand DOAC) will take the participants DOAC for 30 consecutive days following a qualifying AF episode (i.e., greater than1 hour) detected by the AFSW. Participants randomized to the standard of care (control) arm will remain on previously prescribed continuous DOAC throughout the study.

A total of 5350 participants will be enrolled across up to 100 study sites targeting two-thirds academic and one-third private practices, with academic practices also enrolling from affiliated community sites. The investigators anticipate evaluating 7643 consented individuals with external monitoring to ensure that a low AF burden population will be randomized. Up to 200 participants may be enrolled at any one site, and participation will last up to 60 months.

03

Conditions studied

  • Atrial Fibrillation

Keywords

  • Atrial Fibrillation
  • Anticoagulation
  • AF-sensing Smart Watch
  • Ischemic Stroke
  • Systemic Embolism
04

Who can participate

The criteria were revised on the registry on Sep 28, 2026. See what changed

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 22-85 years of age.
  2. English speaking participants. Spanish-only speakers may be included in the future at select sites appropriately translated.
  3. History of non-permanent atrial fibrillation.
  4. CHA2DS2-VASC score of 1-5 for men and 2-5 for women without prior stroke or (TIA), The CHA2DS2-VASc score is a point-based system used to stratify the risk of stroke in Atrial Fibrillation (AF) patients. The acronym CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female). Congestive heart failure defined as: The presence of signs and symptoms of either right (elevated central venous pressure, hepatomegaly, dependent edema) or left ventricular failure (exertional dyspnea, cough, fatigue, orthopnea, paroxysmal nocturnal dyspnea, cardiac enlargement, rales, gallop rhythm, pulmonary venous congestion) or both, confirmed by non-invasive or invasive measurements demonstrating objective evidence of cardiac dysfunction and/or \< 40%.
  5. The participant is on a DOAC at the time of screening and willing to stay on DOAC for duration of study.
  6. Willing and able to comply with the protocol, including:

    • Possession of a smart watch-compatible smart phone (iPhone that supports the latest shipping iOS) with a cellular service plan
    • Be willing to wear the smart watch for the suggested minimum of 14 hours a day
    • Expected to be within cellular service range at least 80% of the time
  7. Willing and able to discontinue DOAC
  8. The participant is willing and able to provide .

Exclusion criteria

Exclusion Criteria:

  1. Valvular or permanent atrial fibrillation.
  2. Current treatment with warfarin and unwilling or unable to take a DOAC.
  3. The participant is a woman who is pregnant or nursing.
  4. The participant is being treated with chronic daily oral NSAIDs and is unwilling or unable to discontinue use for the study duration. Use of low-dose aspirin is permitted.
  5. Existing cardiac rhythm device or indication for a permanent pacemaker, Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT) device or planned insertable cardiac monitor. Insertable cardiac monitors are permitted unless they are being used to guide anticoagulation treatment.
  6. Known or suspected symptomatic or asymptomatic atrial fibrillation lasting ≥ 1 hour/month over the last 3 months.
  7. Any documented single AF episode lasting ≥ 1 hour on a cardiac monitor performed within 90 days prior to randomization.
  8. Ablation for AF within the last 2 months.
  9. Prior or anticipated left atrial appendage occlusion or ligation.
  10. Mechanical prosthetic valve(s) or severe valve disease.
  11. Hypertrophic cardiomyopathy.
  12. Participant needs DOAC for reasons other than preventing stroke or arterial embolism resulting from AF (i.e., preventing Deep Vein Thrombosis (DVT) or PE) or needs permanent OAC (i.e., congenital heart defects, prosthetic heart valve).
  13. Participants deemed high risk for non-cardioembolic stroke (i.e., significant carotid artery disease defined as stenosis > 75%) based on the investigator's discretion.
  14. The participant is enrolled, has participated within the last 30 days, or is planning to participate in a concurrent drug and/or device study during the course of this clinical trial. Co-enrollment in concurrent trials is only allowed with documented pre-approval from the study manager; there is no concern that co-enrollment could confound the results of this trial.
  15. The participant has a tattoo, birthmark, or surgical scar over the dorsal wrist area on the ipsilateral side that the AFSW may be worn.
  16. The participant has a tremor on their ipsilateral side that the AFSW may be worn.
  17. Any concomitant condition that, in the investigator's opinion, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse).
  18. Known or to direct oral anticoagulants.
  19. Documented prior stroke (ischemic or hemorrhagic) or .
  20. Reversible causes of AF (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism). AF ablation does not constitute reversible AF.
  21. > 5% burden of premature atrial or ventricular depolarizations on pre-enrollment cardiac monitoring.
  22. History of -documented, sustained atrial flutter that has not been treated with ablation (participants with atrial flutter who have been ablated are eligible for enrollment)
  23. Stage 4 or 5 chronic kidney disease.
  24. Conditions associated with an increased risk of bleeding:

    • Major surgery in the previous month
    • Planned surgery or intervention in the next three months that would require cessation of anticoagulation > 2 weeks.
    • History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intra- articular bleeding
    • Gastrointestinal hemorrhage within the past year unless the cause has been permanently eliminated (e.g., by surgery)
    • Symptomatic or endoscopically documented gastroduodenal ulcer disease in the previous 30 days
    • Hemorrhagic disorder or bleeding diathesis
    • Need for anticoagulant treatment for disorders other than AF
    • Uncontrolled hypertension (Systolic Blood Pressure >180 mmHg and/or Diastolic Blood Pressure >100 mmHg)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
5,350 participants (estimated)

Study arms

  • Experimental
    AFSW Guided DOAC

    All participants randomized to the experimental arm will be provided with an AFSW that will be linked to the participants Apple watch and the secure REACT-AF app within the Eureka cloud. The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.

    Device: AFSW Guided DOAC

  • Active comparator
    Continuous DOAC therapy

    All participants randomized to the control arm will remain on previously prescribed FDA-approved DOAC regimen as indicated by current practice standards. These participants will continuously take DOAC through the course of the study as prescribed by the participants primary physician unless otherwise contraindicated. Participants in the control arm will also use the REACT-AF mobile app within the Eureka platform via Apple watch for study follow-up activities, but the participants will not receive an AFSW and any personally owned Apple Watch will not be loaded with the customized REACT-AF detection algorithm nor participant notification apps.

    Drug: Continuous DOAC therapy

Interventions

  • DeviceAFSW Guided DOAC

    The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.

    Also known as: Apple Watch

  • DrugContinuous DOAC therapy

    DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.

    Also known as: Oral Anticoagulation therapy

06

What researchers measure

Primary outcomes

  1. To assess whether AFSW-guided, time-delimited DOAC therapy is non-inferior to continuous DOAC therapy for a composite endpoint that includes: (1) Ischemic stroke; (2) Systemic embolism; (3) All-cause mortality.

    The primary objective (efficacy objective) of the REACT-AF trial is to assess whether AFSW-guided, time-delimited DOAC therapy is non-inferior to continuous DOAC therapy for a composite endpoint that includes: (1) Ischemic stroke; (2) Systemic embolism; and (3) All-cause mortality. Stroke is defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction; and classified as ischemic, hemorrhagic, or cause unknown based on CT or Magnetic Resonance (MR) scanning or autopsy. Systemic embolism is defined as an acute vascular occlusion of the extremities or any organ and must be documented by angiography, surgery, scintigraphy, or autopsy and require hospitalization. All-cause mortality will be defined as the underlying disease or injury that initiates the train of events resulting in death.

    Time frame: At 60 months

Secondary outcomes

  1. To assess whether AFSW-guided, time-delimited DOAC therapy significantly reduces major bleeding events compared to continuous DOAC therapy.

    Oral anticoagulation carries a risk of major bleeding, including life-threatening hemorrhage, the intervention is expected to reduce the safety endpoint, major bleeding, by \> 35%, and the study is powered for the superiority of the safety endpoint. Major bleeding will be defined as requiring hospitalization and by ≥1 of the following International Society on Thrombosis and Haemostasis (ISTH) criteria: (1) Bleeding associated with a reduction in hemoglobin level of at least 2.0 g/dL; (2) Bleeding leading to transfusion of at least two units of blood or packed cells; or (3) Symptomatic bleeding in a critical area or organ such as intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding.

    Time frame: At 60 months

07

Study locations

84 of 93 sites recruiting
08

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jul 2029, 72 months after the start.

Of 62 non-industry phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's planned 72 months is above that.

Counting every sponsor, half of 83 studies reached it within 42 months; a quarter within 32 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2023
First posted
May 1, 2023
StartActual
Jul 13, 2023
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed. Sarasota Memorial Health Care System is now Active, not recruiting
Show 2 added (2 United States)
  • Johns Hopkins University · Baltimore, United States
  • St. Elizabeth's Medical Center · Boston, United States
Show 2 removed
  • St. Elizabeth's Medical Center · Washington D.C., United States
  • Johns Hopkins Univeristy · Baltimore, United States
across 2 updates, Sep 28, 2026 – Nov 3, 2026
Eligibility
1 inclusion criterion edited; 3 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedCHA2DS2-VASC score of 1-45 for men and 2-45 for women without prior stroke or Transient Ischemic Attack (TIA), The CHA2DS2-VASc score is a point-based system used to stratify the risk of stroke in Atrial Fibrillation (AF) patients. The acronym CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female). Congestive heart failure defined as: The presence of signs and symptoms of either right (elevated central venous pressure, hepatomegaly, dependent edema) or left ventricular failure (exertional dyspnea, cough, fatigue, orthopnea, paroxysmal nocturnal dyspnea, cardiac enlargement, rales, gallop rhythm, pulmonary venous congestion) or both, confirmed by non-invasive or invasive measurements demonstrating objective evidence of cardiac dysfunction and/or ejection fraction < 40%.
Exclusion criteria
  • ChangedBefore The participant is being treated with chronic aspirin, another anti-platelet agent, or chronic NSAIDS outside of current medical guidelines (e.g., primary stroke prevention in patients with atrial fibrillation, primary prevention of cardiovascular events, pain relief, fever, gout) and is unwilling or unable to discontinue use for the study duration.Now The participant is being treated with chronic daily oral NSAIDs and is unwilling or unable to discontinue use for the study duration. Use of low-dose aspirin is permitted.
  • ChangedBefore Any documented single AF episode lasting ≥ 1 hour on standard of care or study-provided external cardiac monitor of > 6 days duration performed within 45 days prior to randomization. Shorter monitoring durations may be acceptable for inclusion at the discretion of the site PI based on the totality of monitoring data and approval of the study PI.Now Any documented single AF episode lasting ≥ 1 hour on a cardiac monitor performed within 90 days prior to randomization.
  • EditedHistory of ECG-documented, sustained atrial flutter that has not been treated with ablation (participants inwith atrial flutter andwho have been ablated are eligible for enrollment).
Sep 28, 2026
Contact
Study contact's phone or email changed: •••6211→none listed. See the current contact
Sep 28, 2026
Site contacts
Changed at 27 sites. See the sites
Show 27 sites
  • Sarasota Memorial Health Care System · Sarasota, United StatesContact removed J•••@smh.comContact removed C•••@smh.comContact removed (no phone or email listed)
  • University of Illinois Chicago · Chicago, United StatesContact y•••@uic.edu→d•••@uic.edu
  • Hackensack Meridian Health · Hackensack, United StatesContact P•••@hmhn.org · •••5722→•••3775Contact person changed (no phone or email listed)Contact none listed→j•••@hmhn.org
  • University of North Carolina · Chapel Hill, United StatesContact •••8644→•••5219Contact removed m•••@med.unc.edu
  • St. Joseph Medical Center Tacoma · Tacoma, United StatesContact b•••@vmfh.org→b•••@commonspirit.org
  • Wake Forest Baptist Health · Winston-Salem, United StatesContact k•••@wakehealth.edu→K•••@advocatehealth.orgContact m•••@wakehealth.edu→T•••@advocatehealth.org · •••7024
  • South Denver Cardiology Associates, P.C. · Littleton, United StatesContact •••2162→•••2053
  • Georgia Arrhythmia Consultants and Research Institute · Warner Robins, United StatesContact h•••@gacri.com→G•••@gacri.com · •••2469Contact added a•••@gacri.com · •••2469
  • The Lindner Center for Research and Education at The Christ Hospital · Cincinnati, United StatesContact removed R•••@thechristhospital.com · •••1777
  • Ohio State University Medical Center · Columbus, United StatesContact k•••@osumc.edu · •••5462→a•••@osumc.edu · •••8650
  • University of Oklahoma Health Sciences Center · Oklahoma City, United StatesContact k•••@ouhsc.edu→S•••@ou.eduContact removed a•••@ouhsc.edu
  • Mayo Clinic · Jacksonville, United StatesContact W•••@mayo.edu · •••8551→M•••@mayo.edu · •••4512
  • Baycare Health Systems Clearwater · Winter Haven, United StatesContact removed l•••@baycare.org · •••1121
  • Loyola University Chicago · Chicago, United StatesContact removed j•••@luc.edu · •••2644
  • Midwest Cardiovascular Institute · Naperville, United StatesContact J•••@cardio.com→J•••@midwestcardio.com
  • BMC - Brighton · Boston, United StatesContact r•••@steward.org · •••2023→K•••@bmc.org · •••9891
  • Henry Ford Health · Detroit, United StatesContact d•••@hfhs.org · •••9575→m•••@hfhs.org · •••1719
  • Trinity Health Grand Rapids/Mercy Health · Grand Rapids, United StatesContact removed N•••@trinity-health.org
  • William Beaumont Hospital · Royal Oak, United StatesContact l•••@corewellhealth.org · •••5589→T•••@corewellhealth.org · •••5471
  • University of Minnesota · Minneapolis, United StatesContact removed d•••@umn.edu · •••4316
  • University at Buffalo · Buffalo, United StatesContact c•••@buffalo.edu · •••4859→none listedContact removed (no phone or email listed)
  • University of Cincinnati College of Medicine · Cincinnati, United StatesContact s•••@ucmail.uc.edu · •••4721→m•••@ucmail.uc.edu · •••4739
  • Allegheny Singer Research Institute · Pittsburgh, United StatesContact e•••@ahn.org · •••3512→S•••@ahn.org · •••5281
  • Penn State Health Medical Group Berks Cardiology · Wyomissing, United StatesContact removed m•••@pennstatehealth.psu.edu · •••8500
  • University of Virginia · Charlottesville, United StatesContact c•••@virginia.edu · •••5677→S•••@uvahealth.org · •••7717
  • James River Cardiology · Richmond, United StatesContact J•••@alignedcardio.com · •••4111→m•••@alignedcardio.com · •••1552
  • University of Wisconsin · Madison, United StatesContact e•••@medicine.wisc.edu · •••6950→m•••@medicine.wisc.edu · •••3653
across 5 updates, Sep 28, 2026 – Nov 3, 2026
Show all 5 updates
  1. Nov 3, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Johns Hopkins University · Baltimore, United States
    • St. Elizabeth's Medical Center · Boston, United States
    Show 2 removed
    • St. Elizabeth's Medical Center · Washington D.C., United States
    • Johns Hopkins Univeristy · Baltimore, United States
    Site contacts Changed at 16 sites. See the sites
    Show 16 sites
    • Mayo Clinic · Jacksonville, United StatesContact W•••@mayo.edu · •••8551→M•••@mayo.edu · •••4512
    • Baycare Health Systems Clearwater · Winter Haven, United StatesContact removed l•••@baycare.org · •••1121
    • Loyola University Chicago · Chicago, United StatesContact removed j•••@luc.edu · •••2644
    • Midwest Cardiovascular Institute · Naperville, United StatesContact J•••@cardio.com→J•••@midwestcardio.com
    • BMC - Brighton · Boston, United StatesContact r•••@steward.org · •••2023→K•••@bmc.org · •••9891
    • Henry Ford Health · Detroit, United StatesContact d•••@hfhs.org · •••9575→m•••@hfhs.org · •••1719
    • Trinity Health Grand Rapids/Mercy Health · Grand Rapids, United StatesContact removed N•••@trinity-health.org
    • William Beaumont Hospital · Royal Oak, United StatesContact l•••@corewellhealth.org · •••5589→T•••@corewellhealth.org · •••5471
    • University of Minnesota · Minneapolis, United StatesContact removed d•••@umn.edu · •••4316
    • University at Buffalo · Buffalo, United StatesContact c•••@buffalo.edu · •••4859→none listedContact removed (no phone or email listed)
    • University of Cincinnati College of Medicine · Cincinnati, United StatesContact s•••@ucmail.uc.edu · •••4721→m•••@ucmail.uc.edu · •••4739
    • Allegheny Singer Research Institute · Pittsburgh, United StatesContact e•••@ahn.org · •••3512→S•••@ahn.org · •••5281
    • Penn State Health Medical Group Berks Cardiology · Wyomissing, United StatesContact removed m•••@pennstatehealth.psu.edu · •••8500
    • University of Virginia · Charlottesville, United StatesContact c•••@virginia.edu · •••5677→S•••@uvahealth.org · •••7717
    • James River Cardiology · Richmond, United StatesContact J•••@alignedcardio.com · •••4111→m•••@alignedcardio.com · •••1552
    • University of Wisconsin · Madison, United StatesContact e•••@medicine.wisc.edu · •••6950→m•••@medicine.wisc.edu · •••3653
    + 1 other change: verification date
  2. Oct 14, 2026
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Georgia Arrhythmia Consultants and Research Institute · Warner Robins, United StatesContact h•••@gacri.com→G•••@gacri.com · •••2469Contact added a•••@gacri.com · •••2469
    • The Lindner Center for Research and Education at The Christ Hospital · Cincinnati, United StatesContact removed R•••@thechristhospital.com · •••1777
    • Ohio State University Medical Center · Columbus, United StatesContact k•••@osumc.edu · •••5462→a•••@osumc.edu · •••8650
    • University of Oklahoma Health Sciences Center · Oklahoma City, United StatesContact k•••@ouhsc.edu→S•••@ou.eduContact removed a•••@ouhsc.edu
    + 1 other change: verification date
  3. Sep 30, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • South Denver Cardiology Associates, P.C. · Littleton, United StatesContact •••2162→•••2053
  4. Sep 29, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Wake Forest Baptist Health · Winston-Salem, United StatesContact k•••@wakehealth.edu→K•••@advocatehealth.orgContact m•••@wakehealth.edu→T•••@advocatehealth.org · •••7024
  5. Sep 28, 2026
    Sarasota Memorial Health Care System is now Active, not recruiting
    Eligibility 1 inclusion criterion edited; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedCHA2DS2-VASC score of 1-45 for men and 2-45 for women without prior stroke or Transient Ischemic Attack (TIA), The CHA2DS2-VASc score is a point-based system used to stratify the risk of stroke in Atrial Fibrillation (AF) patients. The acronym CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female). Congestive heart failure defined as: The presence of signs and symptoms of either right (elevated central venous pressure, hepatomegaly, dependent edema) or left ventricular failure (exertional dyspnea, cough, fatigue, orthopnea, paroxysmal nocturnal dyspnea, cardiac enlargement, rales, gallop rhythm, pulmonary venous congestion) or both, confirmed by non-invasive or invasive measurements demonstrating objective evidence of cardiac dysfunction and/or ejection fraction < 40%.
    Exclusion criteria
    • ChangedBefore The participant is being treated with chronic aspirin, another anti-platelet agent, or chronic NSAIDS outside of current medical guidelines (e.g., primary stroke prevention in patients with atrial fibrillation, primary prevention of cardiovascular events, pain relief, fever, gout) and is unwilling or unable to discontinue use for the study duration.Now The participant is being treated with chronic daily oral NSAIDs and is unwilling or unable to discontinue use for the study duration. Use of low-dose aspirin is permitted.
    • ChangedBefore Any documented single AF episode lasting ≥ 1 hour on standard of care or study-provided external cardiac monitor of > 6 days duration performed within 45 days prior to randomization. Shorter monitoring durations may be acceptable for inclusion at the discretion of the site PI based on the totality of monitoring data and approval of the study PI.Now Any documented single AF episode lasting ≥ 1 hour on a cardiac monitor performed within 90 days prior to randomization.
    • EditedHistory of ECG-documented, sustained atrial flutter that has not been treated with ablation (participants inwith atrial flutter andwho have been ablated are eligible for enrollment).
    Contact Study contact's phone or email changed: •••6211→none listed. See the current contact
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Sarasota Memorial Health Care System · Sarasota, United StatesContact removed J•••@smh.comContact removed C•••@smh.comContact removed (no phone or email listed)
    • University of Illinois Chicago · Chicago, United StatesContact y•••@uic.edu→d•••@uic.edu
    • Hackensack Meridian Health · Hackensack, United StatesContact P•••@hmhn.org · •••5722→•••3775Contact person changed (no phone or email listed)Contact none listed→j•••@hmhn.org
    • University of North Carolina · Chapel Hill, United StatesContact •••8644→•••5219Contact removed m•••@med.unc.edu
    • St. Joseph Medical Center Tacoma · Tacoma, United StatesContact b•••@vmfh.org→b•••@commonspirit.org
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05836987
Responsible party
Sponsor
First posted
May 1, 2023
Start date
Jul 13, 2023
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Shea Smith
Contact
sgluhm@stanford.edu
Rod Passman
principal investigator · Northwestern University
Dan Hanley
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion